Olivia Vizier

pharmas almanac

Addressing Cancer Therapy Resistance by Targeting Translational Regulation

At the inception of eFFECTOR, one of the key considerations was that, to extend the duration of benefit of a given treatment, you have to contend with resistance. It had become clear that, even when using the most tightly targeted therapy or immunotherapy, resistance happens. I’ve spent about 15 years in the antiviral world working

Addressing Cancer Therapy Resistance by Targeting Translational Regulation Read More »

Sugar pill that’s not a placebo could be key to broad metabolic reset

Swiss biopharma startup Aphaia Pharma AG is taking the concept of “location, location, location” to its extreme. The company started dosing patients in a phase II trial of its lead candidate, Aph-012, in late April, 2023. The trial is a randomized, double-blind, placebo-controlled, multicenter proof-of-concept study to evaluate Aph-012’s ability to improve glucose tolerance in

Sugar pill that’s not a placebo could be key to broad metabolic reset Read More »

In Vivo’s 2023 Rising Leaders: Healthcare Innovators At The Top Of Their Game

Araris Biotech is using this linker technology to develop next-generation ADCs with the potential to be safer and more efficacious for cancer patients. In head-to-head animal model studies against FDA approved ADCs, the ADCs created using Araris’ linker technology demonstrated improved efficacy, even at low doses, as well as high tolerability.

In Vivo’s 2023 Rising Leaders: Healthcare Innovators At The Top Of Their Game Read More »

Delivering on the need for vector innovation in genetic medicine

Viruses are masters at delivering genetic material to the nucleus of the organisms they infect, and because of this, they were the first vectors that were developed for gene therapy delivery. A plethora of viral vectors entered the gene therapy arena including lentiviruses, retroviruses, herpes simplex viruses, adenoviruses and adeno-associated viruses. Each of these vector

Delivering on the need for vector innovation in genetic medicine Read More »

New macrophage switching nanomedicine D-4559 developed by Ashvattha Therapeutics

Tumor-infiltrating myeloid cells such as tumor-associated macrophages (TAMs) can suppress T-cell recruitment and function and promote the expansion and dissemination of cancer cells depending on their functional states. In hepatocellular carcinoma (HCC), TAMs are associated with resistance to sorafenib, the first-line treatment for advanced HCC.

New macrophage switching nanomedicine D-4559 developed by Ashvattha Therapeutics Read More »

Longevity Technology

Life Biosciences presents data demonstrating restoration of visual function in nonhuman primates

Life Biosciences, a biotech advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury, has announced preclinical data in nonhuman primates (NHP) for its novel gene therapy candidate which uses a partial epigenetic reprogramming approach to restore visual function.

Life Biosciences presents data demonstrating restoration of visual function in nonhuman primates Read More »

pharma shots

James Graham, CEO of Recce Pharmaceuticals Shares Insights from the Expansion and Acceleration of Clinical Programs

Our lead anti-infective candidate, RECCE® 327 (R327), will be advancing into a Phase Ia/IIb intravenous multiple ascending dose safety and tolerability study and a Phase II clinical trial investigating the efficacy of R327 against diabetic foot ulcer (DFU) infections.

James Graham, CEO of Recce Pharmaceuticals Shares Insights from the Expansion and Acceleration of Clinical Programs Read More »

Fierce-Biotech

Glimpse of success? Life Biosciences’ gene therapy restores visual function in primates with eye disorder

Life Biosciences’ gene therapy platform works by inducing expression of the transcription factors Oct3/4, Sox2 and Klfr4, or OSK—three of the four Yamanaka factors. When all four Yamanaka factors are expressed together, have been shown to fully reprogram differentiated human, mouse and primate cells back into pluripotent stem cells, erasing their cell identity and resetting

Glimpse of success? Life Biosciences’ gene therapy restores visual function in primates with eye disorder Read More »

Benzinga

eFFECTOR Therapeutics Collaborates With Stanford Medicine Mid-Stage Breast Cancer Study

eFFECTOR Therapeutics Inc will collaborate with Stanford Medicine on an investigator-initiated randomized Phase 2 study evaluating zotatifin in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a preoperative setting.

eFFECTOR Therapeutics Collaborates With Stanford Medicine Mid-Stage Breast Cancer Study Read More »

biospace

World Vaccine Congress Panel Highlights Exigency of AMR Global Health Crisis

Another expert in the space, Emma Harvey, M.D., Global Head of Medical Affairs, F2G, concurred.Harvey focuses on antifungal resistance, a type of antimicrobial resistance that occurs when fungi become resistant to antifungal agents. The results of antifungal resistance on human health are similar to that of AMR, including treatment failures, prolonged illness and even death,

World Vaccine Congress Panel Highlights Exigency of AMR Global Health Crisis Read More »